Herbert H. Loong
YOU?
Author Swipe
View article: 523 Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC
523 Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC Open
View article: Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer Open
Exon 20 insertions of HER2, encoded by erb-b2 receptor tyrosine kinase 2 (ERBB2), and other activating HER2 mutations occur in 2% to 4% of lung adenocarcinomas, but there are only limited therapeutic options available for these patients. S…
View article: BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study
BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study Open
BOS172738 showed preliminary efficacy and a manageable safety profile in RET-altered tumors, including those resistant to prior therapies and in patients with brain metastases.
View article: Spinal Metastasis from Supratentorial Glioblastoma: A Registry-Based Case Series and a Review of the Literature
Spinal Metastasis from Supratentorial Glioblastoma: A Registry-Based Case Series and a Review of the Literature Open
Background: Spinal metastasis is a rare complication of supratentorial glioblastoma. We report the clinical features and prognosis of this phenomenon and review the relevant literature. Methods: This is a territory-wide, multicentre, retro…
View article: 19P Developing a multi-lingual clinical trial matching platform by large language models in the Hong Kong Special Administrative Region
19P Developing a multi-lingual clinical trial matching platform by large language models in the Hong Kong Special Administrative Region Open
View article: Enhancing cost-effectiveness considerations in the adoption of new drugs in Hong Kong
Enhancing cost-effectiveness considerations in the adoption of new drugs in Hong Kong Open
View article: Association Between Comorbidity Clusters and Mortality in Patients With Cancer: Predictive Modeling Using Machine Learning Approaches of Data From the United States and Hong Kong
Association Between Comorbidity Clusters and Mortality in Patients With Cancer: Predictive Modeling Using Machine Learning Approaches of Data From the United States and Hong Kong Open
Background Patients with cancer and cancer survivors often experience multiple chronic health conditions, which can impact symptom burden and treatment outcomes. Despite the high prevalence of multimorbidity, research on cancer prognosis h…
View article: First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion–Positive NSCLC: A LIBRETTO-431 Subgroup Analysis
First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion–Positive NSCLC: A LIBRETTO-431 Subgroup Analysis Open
View article: Incorporating High-Risk Individuals Beyond Smoking History Into Lung Cancer Screening in Hong Kong: A Cost-Effectiveness Study
Incorporating High-Risk Individuals Beyond Smoking History Into Lung Cancer Screening in Hong Kong: A Cost-Effectiveness Study Open
View article: Psychosocial challenges among Asian adolescents and young adults with cancer: a scoping review
Psychosocial challenges among Asian adolescents and young adults with cancer: a scoping review Open
View article: Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy
Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy Open
View article: Impact of alternating electric fields therapy for newly diagnosed WHO grade 4 astrocytoma on patient survival: a real-world propensity-score adjusted prospective multicenter study
Impact of alternating electric fields therapy for newly diagnosed WHO grade 4 astrocytoma on patient survival: a real-world propensity-score adjusted prospective multicenter study Open
Purpose Alternating electric fields (AEF) therapy in addition to temozolomide chemoradiotherapy (TMZ CRT) is increasingly being recommended as first-line treatment for patients with newly-diagnosed WHO grade 4 astrocytoma. However, few hav…
View article: 79P Pre-clinical study of tumor treating fields (TTFields) alone or in conjunction with systemic therapies in selected bone- and soft-tissue sarcomas
79P Pre-clinical study of tumor treating fields (TTFields) alone or in conjunction with systemic therapies in selected bone- and soft-tissue sarcomas Open
View article: Strengthening lung cancer screening in Hong Kong: policy, innovation, and collaborative approaches for early detection and improved outcomes
Strengthening lung cancer screening in Hong Kong: policy, innovation, and collaborative approaches for early detection and improved outcomes Open
View article: Selpercatinib in <i>RET</i> Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial
Selpercatinib in <i>RET</i> Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial Open
LIBRETTO-001 (ClinicalTrials.gov identifier: NCT03157128 ) is a registrational phase I/II, single-arm, open-label trial of selpercatinib in RET-dependent cancers. With 19 months of additional follow-up, we report the final efficacy and saf…
View article: Treatment Efficacy of Genome-Guided Targeted Therapy Versus Chemotherapy in Egfr Mutation Positive Non-Small Cell Lung Cancer after Osimertinib Resistance
Treatment Efficacy of Genome-Guided Targeted Therapy Versus Chemotherapy in Egfr Mutation Positive Non-Small Cell Lung Cancer after Osimertinib Resistance Open
View article: Perceptions in 3.6 Million Web-Based Posts of Online Communities on the Use of Cancer Immunotherapy: Data Mining Using BERTopic
Perceptions in 3.6 Million Web-Based Posts of Online Communities on the Use of Cancer Immunotherapy: Data Mining Using BERTopic Open
Background Immunotherapy has become a game changer in cancer treatment. The internet has been used by patients as a platform to share personal experiences and seek medical guidance. Despite the increased utilization of immunotherapy in cli…
View article: International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms
International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms Open
The aim of the study was to report the outcome of primary localized low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid LGFMS/SEF (H-LGFMS/SEF). Patients with primary localized LGFMS, SEF, or H-LGFM…
View article: Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma Open
Importance The combination of ifosfamide and etoposide (IE) is commonly used to treat relapsed or refractory osteosarcoma; however, second-line treatment recommendations vary across guidelines. Objective To evaluate whether the addition of…
View article: Association between fish oil and glucosamine use and mortality in patients diagnosed with cancer: the role of the Life Essential 8 score and cancer prognosis
Association between fish oil and glucosamine use and mortality in patients diagnosed with cancer: the role of the Life Essential 8 score and cancer prognosis Open
View article: Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group
Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group Open
View article: Lung cancer in Asia: the impact of climate change
Lung cancer in Asia: the impact of climate change Open
The escalating global threat of climate change is becoming more evident. The climate crisis intersects with another major challenge: lung cancer. With Asia already bearing half the global cancer burden, the impact of climate-related events…
View article: Synergistic activities of Panobinostat and doxorubicin in soft tissue sarcomas
Synergistic activities of Panobinostat and doxorubicin in soft tissue sarcomas Open
Synergy effect of LBH589 plus doxorubicin was successfully validated in STS cell lines and an epithelioid sarcoma mice model. We tried to reduce the dose of doxorubicin to a lower level and found the drug combination can still inhibit tumo…
View article: Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Open
View article: Perception of Online Communities towards the Use of Cancer Immunotherapy: A Data Mining Study of 3.6 Million Web-based Posts from Social Media Platforms Using BERTopic (Preprint)
Perception of Online Communities towards the Use of Cancer Immunotherapy: A Data Mining Study of 3.6 Million Web-based Posts from Social Media Platforms Using BERTopic (Preprint) Open
UNSTRUCTURED Immunotherapy has become a game changer in cancer treatment. Few studies have investigated the perceptions about its use by analyzing social media data. This study aimed to use a topic modeling technique, BERTopic, to explore…
View article: Effectiveness of a self‐determination theory‐based smoking cessation intervention plus instant messaging via mobile application for smokers with cancer: Protocol for a pragmatic randomized controlled trial
Effectiveness of a self‐determination theory‐based smoking cessation intervention plus instant messaging via mobile application for smokers with cancer: Protocol for a pragmatic randomized controlled trial Open
Background and aims Despite evidence that patients living with cancer who continue to smoke after diagnosis are at higher risk for all‐cause mortality and reduced treatment efficacy, many cancer patients continue to smoke. This protocol is…
View article: NTRK gene fusion testing and management in lung cancer
NTRK gene fusion testing and management in lung cancer Open
Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are recurrent oncogenic drivers found in a variety of solid tumours, including lung cancer. Several tropomyosin receptor kinase (TRK) inhibitors have been developed to treat tumours…
View article: 53O Results from a phase II part I trial of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, in patients with advanced refractory sarcoma
53O Results from a phase II part I trial of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, in patients with advanced refractory sarcoma Open
AXL is a cell-surface receptor tyrosine kinase highly expressed in several sarcoma subtypes that has been associated with tumor resistance to chemotherapy. Mecbotamab vedotin (BA3011) is a conditionally active biologic anti-AXL antibody-dr…
View article: 35P Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer
35P Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer Open
Selpercatinib is a highly selective and potent CNS-active RET kinase inhibitor approved for the treatment of RET fusion-positive NSCLC based on the results of the phase I/II trial LIBRETTO-001 (NCT03157128). The final LIBRETTO-001 data for…
View article: Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease
Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease Open
The risk of recurrent ILD was considerably higher with osimertinib rechallenge than erlotinib. Osimertinib rechallenge should be avoided, whereas erlotinib may be considered in patients with symptomatic osimertinib-induced ILD.